Given the prevalent use of immune checkpoint inhibitors (ipilimumab, pembrolizumab, nivolumab etc), there will be more demands for PD-L1 testing. We offer this test along with appropriate interpretation. Here, we include sample reports for both lung and non-pulmonary carcinomas so you know what to expect when ordering this assay.
Reporting for pulmonary carcinomas should include strength of staining. The sum of positive inflammatory and tumor cells should be reported as a proportion of the number of tumor cells in nonpulmonary carcinomas (the so-called Combined Positive Score (CPS)).